198 related articles for article (PubMed ID: 8236155)
1. The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models.
Bacher P; Walenga JM; Iqbal O; Bajusz S; Breddin K; Fareed J
Thromb Res; 1993 Aug; 71(4):251-63. PubMed ID: 8236155
[TBL] [Abstract][Full Text] [Related]
2. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
3. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Elg M; Gustafsson D; Deinum J
Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
[TBL] [Abstract][Full Text] [Related]
4. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.
Fareed J; Walenga JM; Iyer L; Hoppensteadt D; Pifarre R
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):135-47. PubMed ID: 1772981
[TBL] [Abstract][Full Text] [Related]
5. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
Deschênes I; Finkle CD; Winocour PD
Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
[TBL] [Abstract][Full Text] [Related]
7. Hirudin as alternative anticoagulant--a historical review.
Markwardt F
Semin Thromb Hemost; 2002 Oct; 28(5):405-14. PubMed ID: 12420235
[TBL] [Abstract][Full Text] [Related]
8. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
[TBL] [Abstract][Full Text] [Related]
9. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
10. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
11. Experimental studies on a recombinant hirudin, CGP 39393.
Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
[TBL] [Abstract][Full Text] [Related]
12. Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model.
Krupinski K; Breddin HK
Haemostasis; 1991; 21 Suppl 1():88-92. PubMed ID: 1894199
[TBL] [Abstract][Full Text] [Related]
13. Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
Cirillo R; Lippi A; Subissi A; Agnelli G; Criscuoli M
Thromb Haemost; 1996 Sep; 76(3):384-92. PubMed ID: 8883275
[TBL] [Abstract][Full Text] [Related]
14. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
15. The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits.
Lu WF; Mo W; Liu Z; Fu WG; Guo DQ; Wang YQ; Song HY
Thromb Res; 2010 Oct; 126(4):e339-43. PubMed ID: 20483158
[TBL] [Abstract][Full Text] [Related]
16. Leeches to hirulogs and other thrombin-directed antithrombotics.
Fenton JW
Hematol Oncol Clin North Am; 1992 Oct; 6(5):1121-9. PubMed ID: 1400076
[TBL] [Abstract][Full Text] [Related]
17. Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature.
Liu JT; Paul W; Emerson M; Cicala C; Page CP
Eur J Pharmacol; 1994 Oct; 264(2):183-90. PubMed ID: 7851481
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic action of recombinant hirudin in a venous thrombosis model.
Raake W; Klauser RJ; Elling H; Zeiller P
Haemostasis; 1991; 21 Suppl 1():127-32. PubMed ID: 1654293
[TBL] [Abstract][Full Text] [Related]
19. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
Fareed J; Walenga JM; Pifarre R; Hoppensteadt D; Koza M
Haemostasis; 1991; 21 Suppl 1():64-72. PubMed ID: 1894198
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
